Response to ''To switch or not to switch': the missing piece in the puzzle of biosimilar literature?' by Scherlinger et al

Ann Rheum Dis. 2020 Apr;79(4):e37. doi: 10.1136/annrheumdis-2018-214952. Epub 2019 Jan 23.
No abstract available

Keywords: DMARDs (biologic); anti-TNF; disease activity; outcomes research.

Publication types

  • Letter
  • Comment

MeSH terms

  • Antirheumatic Agents*
  • Biosimilar Pharmaceuticals*
  • Etanercept
  • Humans
  • Registries
  • Treatment Outcome


  • Antirheumatic Agents
  • Biosimilar Pharmaceuticals
  • Etanercept